RESUMO
A case of a 49-year-old male with exacerbation of eosinophilic granulomatosis with polyangiitis (EGPA) with heart involvement mimicking acute coronary syndrome is presented. Institution of intensive immunosupresive treatment resulted in the improvement of clinical condition and systolic left ventricular function. Coronary angiography excluded atherosclerosis as a primary cause of heart damage.
Assuntos
Síndrome de Churg-Strauss/diagnóstico , Disfunção Ventricular Esquerda/diagnóstico , Síndrome Coronariana Aguda/diagnóstico , Angiografia Coronária , Diagnóstico Diferencial , Eletrocardiografia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
INTRODUCTION Leukotrienes (LTs) may be involved in atherosclerosis and may contribute to cardiovascular outcomes in CAD. OBJECTIVES We aimed to compare the baseline LT production in patients with stable CAD (sCAD) and myocardial infarction (MI), and to assess whether an increased LT production is associated with major adverse cardiovascular events (MACEs) at 1 year after MI. PATIENTS AND METHODS LTIMI (Leukotrienes and Thromboxane In Myocardial Infarction) was a singlecenter, prospective, observational study of patients with stable sCAD and MI. Urinary leukotriene E4 (LTE4) levels were measured on admission, at 1 month, and at 1 year, using highperformance liquid chromatography tandem mass spectrometry. RESULTS Of the 404 patients screened, 289 were enrolled (110 with sCAD and 179 with MI; mean [SD] age, 63.9 [10.9] years). Patients with MI had higher median (interquartile range [IQR]) levels of logtransformed LTE4 (logLTE4) than those with sCAD (4.74 pg/mg creatinine [4-5.45] vs 4.51 pg/mg creatinine [3.99 4.86], respectively; P <0.001). Median (IQR) logLTE4 levels in patients with MI significantly decreased at 1 month to 4.37 pg/mg creatinine (3.81-4.95), and at 1 year to 4.16 pg/mg creatinine (3.55-4.85). The baseline urinary logLTE4 levels were similar in patients with MACEs and those without MACEs (median [IQR], 4.78 pg/mg creatinine [4.01-5.56]) and 4.68 pg/mg creatinine [3.97-5.28], respectively; P >0.05). Multiple regression showed no relation between LTE4 levels and the incidence of MACEs. CONCLUSIONS LT production assessed by urinary LTE4 excretion is higher in patients with MI than in those with sCAD; however, LTE4 levels at baseline do not differ between patients with and without MACEs at 1 year after MI.
Assuntos
Doença da Artéria Coronariana/metabolismo , Leucotrieno E4/biossíntese , Infarto do Miocárdio/metabolismo , Idoso , Doença da Artéria Coronariana/urina , Feminino , Humanos , Leucotrieno E4/urina , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/urina , Estudos ProspectivosRESUMO
BACKGROUND: Urinary 11-dehydro-thromboxane (TX)B2 has been described as a potential predictive biomarker of major adverse cardiovascular events (MACEs) in high cardiac risk patients. This part of LTIMI (Leukotrienes and Thromboxane In Myocardial Infarction) study aimed to evaluate the relationship between 11-dehydro-TXB2 and MACEs in patients with acute myocardial infarction (AMI). METHODS AND RESULTS: LTIMI was an observational, prospective study in 180 consecutive patients with AMI type 1 referred for primary percutaneous coronary intervention. On admission and at follow-up visits (1 month, 1 year), 11-dehydro-TXB2 was measured in urinary samples by using high-performance liquid chromatography-tandem mass spectrometry. The primary outcome was occurrence of composite MACEs during 1-year after AMI. Left ventricular ejection fraction was assessed in echocardiography on admission and at 1-year follow-up. Analyses of 11-dehydro-TXB2 (pg/mg creatinine) were performed on log-transformed data and expressed as median with IQR (Q1-Q3). 11-Dehydro-TXB2 level on admission was 7.39 (6.85-8.01) and decreased at 1 month (6.73, 6.27-7.12; P<0.001) and 1-year follow-up (6.37, 5.91-6.94; P<0.001). In univariate analysis, baseline 11-dehydro-TXB2 was higher in patients with MACEs (n=60; 7.73, 7.07-8.60) compared with those without MACEs (n=119; 7.28, 6.68-7.79; P=0.002). In multivariate regression model, 11-dehydro-TXB2 and 3 other variables (diabetes, multivessel disease, and left ventricular ejection fraction) were found to be best 1-year cumulative MACE predictors with odds ratio for 11-dehydro-TXB2 of 1.58 (95% CI 1.095-2.33; P=0.017) and area under the curve (in receiver operating characteristic analysis of 0.8). Baseline 11-dehydro-TXB2 negatively correlated with both left ventricular ejection fraction on admission (R=-0.21; P=0.006) and after 1 year (R=-0.346; P<0.001). CONCLUSIONS: 11-Dehydro-TXB2 predicts 1-year cumulative MACEs in AMI patients and provides prognostic information on the left ventricular performance.
Assuntos
Isquemia Miocárdica/urina , Tromboxano B2/análogos & derivados , Doença Aguda , Idoso , Biomarcadores/urina , Ecocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/diagnóstico , Isquemia Miocárdica/diagnóstico por imagem , Prognóstico , Estudos Prospectivos , Volume Sistólico , Tromboxano B2/urina , Fatores de TempoRESUMO
Delayed diagnosis in patients with Churg-Strauss syndrome (CSS) is largely attributed to the variable and nonspecific presentation of the disease's initial symptoms. The aim of the study was to evaluate the effect of delayed diagnosis on the course of CSS. We conducted a retrospective study of 30 CSS patients followed up in our department. In each patient, we assessed the delay in CSS diagnosis (the time when patients already fulfilled four out of six of the American College of Rheumatology criteria and the diagnosis was not yet established), the disease activity at the time of diagnosis, and organ involvement during CSS course. A median value of 2 weeks was chosen as the cutoff point after which the diagnosis was considered as delayed. Sixteen patients were diagnosed before (group 1) and 14 patients after this cutoff point (group 2). In group 2, we found a higher Birmingham Vasculitis Activity Score at the moment of diagnosis (20.4 vs 25.1, p < 0.05) and a more severe disease course, resulting in more frequent hospitalization rates (0.64 vs 2.26/year, p < 0.00001), higher corticosteroids dose requirements (5.87 vs 11.57 mg/day converted to methylprednisolone, p < 0.0001), and additional immunosuppressive therapy administration (56.2 vs 92.8 %, p < 0.05) to maintain disease remission. All six perinuclear pattern of antineutrophil cytoplasmic antibobodies (pANCA)-positive patients (20 %) were found in group 1. Concluding, the delay in diagnosis of CSS of more than 2 weeks was found to be associated with a disease course that was more severe. The presence of the pANCA antibodies may occasionally facilitate establishment of the diagnosis.
Assuntos
Síndrome de Churg-Strauss/diagnóstico , Síndrome de Churg-Strauss/tratamento farmacológico , Diagnóstico Tardio/efeitos adversos , Gerenciamento Clínico , Progressão da Doença , Índice de Gravidade de Doença , Corticosteroides/uso terapêutico , Adulto , Anti-Inflamatórios/uso terapêutico , Anticorpos/sangue , Anticorpos Anticitoplasma de Neutrófilos/imunologia , Síndrome de Churg-Strauss/imunologia , Feminino , Seguimentos , Hospitalização/estatística & dados numéricos , Humanos , Imunossupressores/uso terapêutico , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Lead-dependent infective endocarditis (LDIE) has emerged as a serious complication of electrotherapy in the era of advanced medical technology and is a growing problem due to greater patient longevity, limited electrode life-time, an increasing number of abandoned leads, and subclinical symptoms. We present a case of dramatic course of LDIE in a 26 year-old patient in whom standard management had failed to cure endocarditis. This case was complicated by extensive pulmonary septic emboli and required cardio-thoracic intervention.